You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
McKinsey
Express Scripts
Moodys
McKesson

Last Updated: May 10, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SOOLANTRA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Soolantra

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01493947 CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study Completed Galderma R&D Phase 3 2012-04-01 Study objectives: - To compare efficacy and safety of Ivermectin 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea after 16-week topical treatment. - And to compare, for subjects initially successfully treated by 16 weeks treatment, Ivermectin 1 % cream versus metronidazole 0.75% cream during a 36-week extension period by assessing, the time of first relapse, the relapse rate, and the number of days free of treatment
NCT02616250 MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. Active, not recruiting Galderma Phase 4 2015-12-01 The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.
NCT02806414 Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation. Not yet recruiting Galderma Phase 1/Phase 2 2016-07-01 This study will assess the role of topical Ivermectin 1% cream and its effect on protease and antimicrobial peptide expression in rosacea. This is a single-site 16-week open label study at University of California, San Diego. The investigators will do this by first measuring serine protease activity and cathelicidin of all subjects. All subjects will receive Ivermectin topical cream and will be instructed on how to apply it daily for 12 weeks. Participants will return for monthly visits during which their clinical symptoms of facial redness and number of facial papules will be scored, and they will have repeat tape stripping. At the end of the study, tape strips will be analyzed to determine serine protease activity of participants at each of their visits and expression of cathelicidin (LL-37) mRNA. The investigators will then look at changes in serine protease activity and LL-37 expression over time, and they will also determine whether or not these changes correlate with disease severity.
NCT02806414 Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation. Not yet recruiting University of California, San Diego Phase 1/Phase 2 2016-07-01 This study will assess the role of topical Ivermectin 1% cream and its effect on protease and antimicrobial peptide expression in rosacea. This is a single-site 16-week open label study at University of California, San Diego. The investigators will do this by first measuring serine protease activity and cathelicidin of all subjects. All subjects will receive Ivermectin topical cream and will be instructed on how to apply it daily for 12 weeks. Participants will return for monthly visits during which their clinical symptoms of facial redness and number of facial papules will be scored, and they will have repeat tape stripping. At the end of the study, tape strips will be analyzed to determine serine protease activity of participants at each of their visits and expression of cathelicidin (LL-37) mRNA. The investigators will then look at changes in serine protease activity and LL-37 expression over time, and they will also determine whether or not these changes correlate with disease severity.
NCT03075891 Oracea Soolantra Association in Patients With Severe Rosacea Recruiting Galderma Phase 4 2017-07-05 The main objective of this study is to evaluate the efficacy of Ivermectin 1% topical cream associated with Doxycycline 40 mg Modified release (MR) capsules versus Ivermectin 1% topical cream associated with Placebo in the treatment of severe Rosacea.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Soolantra

Condition Name

Condition Name for Soolantra
Intervention Trials
Rosacea 3
Papulopustular Rosacea 1
Facial Rosacea 1
COVID-19 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Soolantra
Intervention Trials
Rosacea 5
Facies 1
Inflammation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Soolantra

Trials by Country

Trials by Country for Soolantra
Location Trials
United States 16
Canada 3
Hungary 2
France 1
Poland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Soolantra
Location Trials
California 3
Texas 2
Nebraska 2
Florida 2
Arkansas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Soolantra

Clinical Trial Phase

Clinical Trial Phase for Soolantra
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Soolantra
Clinical Trial Phase Trials
Not yet recruiting 3
Active, not recruiting 1
Completed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Soolantra

Sponsor Name

Sponsor Name for Soolantra
Sponsor Trials
Galderma 3
Zydus Worldwide DMCC 1
Catawba Research, LLC 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Soolantra
Sponsor Trials
Industry 5
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Medtronic
Dow
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.